Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration has approved Opdivo in combination with Yervoy for the treatment of patients with BRAF V600 wild-type and BRAF ...
Opdivo showed superior long-term efficacy over Yervoy in resected stage 3B-4 melanoma, with improved RFS and DMFS outcomes. Median OS and MSS were not reached, but data favored Opdivo, suggesting a ...
Patients experienced a 38% reduction in the risk of disease progression or death when treated with Opdivo plus Yervoy versus Opdivo monotherapy across all lines of therapy at median 47 months of ...
Zacks Investment Research on MSN
Here's Why Replimune Stock Skyrockets Nearly 131% in 3 Months
Shares of Replimune Group REPL have surged 131.1% over the past three months, fueled by positive regulatory updates. In October, the FDA accepted the resubmission of the biologics license application ...
Bristol Myers Squibb Presents Results from CheckMate -8HW Analysis Evaluating Opdivo® (nivolumab) plus Yervoy® (ipilimumab) Compared to Opdivo Monotherapy in Patients with Microsatellite ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback